A--To Expand the Workscope of the PACT III Program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
This is a Presolicitation for the Production Assistance for Cellular Therapy (PACT) III program, aiming to expand its scope by reintroducing the manufacture and distribution of cellular products for clinical trials. This opportunity is designated as a Women-Owned Small Business (WOSB) Program Set-Aside. It was published on August 9, 2018.
Scope of Work
The primary purpose of this acquisition is to expand the workscope of the PACT III program. This involves reintroducing the manufacture and distribution of cellular products. These products are intended for use in human subjects participating in clinical trials under investigational new drug (IND) applications for the cell product.
Contract & Timeline
- Type: Presolicitation
- Set-Aside: Women-Owned Small Business (WOSB) Program Set-Aside (FAR 19.15)
- Published: August 9, 2018
- Response Due: Not specified at this presolicitation stage.
Evaluation
Details regarding evaluation criteria are not available at this presolicitation stage.
Additional Notes
This notice serves as a preliminary announcement. A formal solicitation, which will include specific requirements, response dates, and full contact information, is anticipated to be released at a later date. Interested WOSB firms should monitor SAM.gov for future updates. The primary contact for this opportunity is Williams, Jeffrey A.